Use of DAT imaging has been suggested as enrichment biomarker for patient selection in early PD clinical trials for eliminating subjects without apparent striatal dopamine nerve terminal loss and thus allowing reduction of trial size [172]. Here, SLC6A3 is linked to Parkinson disease.